729 related articles for article (PubMed ID: 31866073)
21. Euglycemic diabetic ketoacidosis associated with SGLT2i use: Case series.
Puls HA; Haas NL; Franklin BJ; Theyyunni N; Harvey CE
Am J Emerg Med; 2021 Jun; 44():11-13. PubMed ID: 33571749
[TBL] [Abstract][Full Text] [Related]
22. Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature.
Hernandez-Quiles C; Ramirez-Duque N; Acosta-Delgado D
Curr Diabetes Rev; 2019; 15(4):259-262. PubMed ID: 30047331
[TBL] [Abstract][Full Text] [Related]
23. Euglycemic Ketoacidosis.
Bonora BM; Avogaro A; Fadini GP
Curr Diab Rep; 2020 May; 20(7):25. PubMed ID: 32424730
[TBL] [Abstract][Full Text] [Related]
24. Prolonged euglycemic diabetic ketoacidosis triggered by a single dose of sodium-glucose cotransporter 2 inhibitor.
Miwa M; Nakajima M; Kaszynski RH; Goto H
BMJ Case Rep; 2020 Oct; 13(10):. PubMed ID: 33028568
[TBL] [Abstract][Full Text] [Related]
25. [Severe diabetic ketoacidosis, acute kidney injury and dehydration due to canagliflozin in type 2 diabetes mellitus patient: Atypical clinical presentation].
Moreno Obregón F; Espino Montoro A; Marín Martín J; León Jiménez D
Aten Primaria; 2019 Dec; 51(10):664-666. PubMed ID: 31326123
[No Abstract] [Full Text] [Related]
26. Sodium Glucose Cotransporter-2 Inhibitor Treatment and the Risk of Diabetic Ketoacidosis in Denmark: A Retrospective Cohort Study of Five Years of Use.
Laursen HVB; Røikjer JB; Dal J; Jensen MH
Curr Drug Saf; 2021; 16(1):73-81. PubMed ID: 32814538
[TBL] [Abstract][Full Text] [Related]
27. Treatment of a Severe Form of Euglycemic Ketoacidosis in a Patient Treated with SGLT-2 Inhibitors with the Aid of Somatostatin.
Torre A; Bisogno N; Botta C; Caiazza A; D'Angelo F; Del Giudice L; Fiorentini P; Marzano L; Nigro R; Sassone D; Torre P; Vicedomini D
G Ital Nefrol; 2023 Aug; 40(4):. PubMed ID: 37910214
[TBL] [Abstract][Full Text] [Related]
28. Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review.
Thiruvenkatarajan V; Meyer EJ; Nanjappa N; Van Wijk RM; Jesudason D
Br J Anaesth; 2019 Jul; 123(1):27-36. PubMed ID: 31060732
[TBL] [Abstract][Full Text] [Related]
29. Sodium-glucose cotransporter-2-induced euglycemic diabetic ketoacidosis unmasks latent autoimmune diabetes in a patient misdiagnosed with type 2 diabetes mellitus: a case report.
Vadasz B; Arazi M; Shukha Y; Koren O; Taher R
J Med Case Rep; 2021 Feb; 15(1):62. PubMed ID: 33581735
[TBL] [Abstract][Full Text] [Related]
30. The catabolic triad: case report of fasting, major cardiac surgery and sodium-glucose co-transporter 2 inhibitors leading to perioperative euglycaemic ketoacidosis.
Smyth CC; Collins M; McCarthy J; Galvin S
Interact Cardiovasc Thorac Surg; 2021 Aug; 33(3):494-495. PubMed ID: 33961026
[TBL] [Abstract][Full Text] [Related]
31. Euglycaemic diabetic ketoacidosis in patients using sodium-glucose co-transporter 2 inhibitors.
Isaacs M; Tonks KT; Greenfield JR
Intern Med J; 2017 Jun; 47(6):701-704. PubMed ID: 28580740
[TBL] [Abstract][Full Text] [Related]
32. Inpatient Perioperative Euglycemic Diabetic Ketoacidosis Due to Sodium-Glucose Cotransporter-2 Inhibitors - Lessons From a Case Series and Strategies to Decrease Incidence.
Mehta PB; Robinson A; Burkhardt D; Rushakoff RJ
Endocr Pract; 2022 Sep; 28(9):884-888. PubMed ID: 35753675
[TBL] [Abstract][Full Text] [Related]
33. Perioperative implications of sodium-glucose cotransporter-2 inhibitors: a case series of euglycemic diabetic ketoacidosis in three patients after cardiac surgery.
Lau A; Bruce S; Wang E; Ree R; Rondi K; Chau A
Can J Anaesth; 2018 Feb; 65(2):188-193. PubMed ID: 29168157
[TBL] [Abstract][Full Text] [Related]
34. An audit of the effect of SGLT2 inhibitor cessation in a pre-admission clinic before and after Australian Diabetes Society guidelines.
Fookeerah P; Law H; Ali F; Chatten K; Kim C; Cheung NW
Intern Med J; 2021 Jun; 51(6):980-983. PubMed ID: 34155765
[TBL] [Abstract][Full Text] [Related]
35. DIABETIC KETOACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES RECENTLY COMMENCED ON SGLT-2 INHIBITORS: AN ONGOING CONCERN.
Ahmed M; McKenna MJ; Crowley RK
Endocr Pract; 2017 Apr; 23(4):506-508. PubMed ID: 28437153
[TBL] [Abstract][Full Text] [Related]
36. Euglycemic Diabetic Ketoacidosis Associated With Use of SGLT2 Inhibitor After Laparoscopic Roux-en-Y Gastric Bypass.
Yared KE; Mancini GJ
Am Surg; 2021 Dec; 87(12):1997-1999. PubMed ID: 32812784
[No Abstract] [Full Text] [Related]
37. SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission.
Hamblin PS; Wong R; Ekinci EI; Fourlanos S; Shah S; Jones AR; Hare MJL; Calder GL; Epa DS; George EM; Giri R; Kotowicz MA; Kyi M; Lafontaine N; MacIsaac RJ; Nolan BJ; O'Neal DN; Renouf D; Varadarajan S; Wong J; Xu S; Bach LA
J Clin Endocrinol Metab; 2019 Aug; 104(8):3077-3087. PubMed ID: 30835263
[TBL] [Abstract][Full Text] [Related]
38. Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks.
Perry RJ; Shulman GI
J Biol Chem; 2020 Oct; 295(42):14379-14390. PubMed ID: 32796035
[TBL] [Abstract][Full Text] [Related]
39. Euglycemic diabetic ketoacidosis in type 2 diabetes treated with a sodium-glucose cotransporter-2 inhibitor.
Jazi M; Porfiris G
Can Fam Physician; 2016 Sep; 62(9):722-4. PubMed ID: 27629667
[No Abstract] [Full Text] [Related]
40. Life-Threatening Complications Related to Delayed Diagnosis of Euglycemic Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Report of 2 Cases.
Goto S; Ishikawa JY; Idei M; Iwabuchi M; Namekawa M; Nomura T
Am J Case Rep; 2021 Mar; 22():e929773. PubMed ID: 33723205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
